Today: 20 March 2026
Subscribe
Browse Category

Pharmaceuticals 25 January 2026 - 28 January 2026

Pfizer stock dips after Xeljanz lands on Medicare price-talk list, with earnings looming

Pfizer stock dips after Xeljanz lands on Medicare price-talk list, with earnings looming

Pfizer shares fell 1.7% to $26.06 after CMS selected its arthritis drug Xeljanz for Medicare price negotiations, with new prices set for 2028. Xeljanz accounted for about $1.01 billion in Medicare spending in the latest period. Investors await Pfizer’s Feb. 3 quarterly results and a Feb. 28 CMS deadline for drugmakers to sign participation agreements.
28 January 2026
···
GSK share price slips in London as Arexvy EU expansion sinks in; earnings next week in focus

GSK share price slips in London as Arexvy EU expansion sinks in; earnings next week in focus

GSK shares dropped 1.8% to 1,828.5 pence by mid-morning Wednesday in London, reversing gains from earlier in the week. The decline followed news that the European Commission expanded approval of GSK’s RSV vaccine Arexvy to all adults 18 and older. Pfizer also secured similar approval for its RSV shot. Investors await guidance from European health agencies and GSK’s earnings report on February 4.
28 January 2026
···
Why Gilead stock hit a fresh 52-week high as Medicare targets Biktarvy and earnings loom

Why Gilead stock hit a fresh 52-week high as Medicare targets Biktarvy and earnings loom

Gilead Sciences shares rose 2.3% to $140.97 Tuesday, hitting a 52-week high after Medicare named its HIV drug Biktarvy for price negotiations starting in 2028. Trading volume topped 10.5 million shares. CEO Daniel O’Day sold 115,640 shares last week under a pre-set plan. Gilead will report fourth-quarter and full-year results after markets close on Feb. 10.
28 January 2026
···
Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next

Johnson & Johnson stock climbs after fresh FDA Darzalex Faspro nod — what investors watch next

Johnson & Johnson shares rose 1.3% Tuesday after the FDA approved a Darzalex Faspro combination for newly diagnosed multiple myeloma patients ineligible for stem-cell transplants. The S&P 500 closed at a record high, while healthcare stocks broadly fell after a Medicare payment proposal. The U.S. also named 15 drugs for future Medicare price negotiations, increasing pressure on big pharma.
28 January 2026
···
Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly shares closed down 2.3% at $1,039.51 Tuesday, then rose 0.3% after hours. U.S. Medicare officials named Lilly’s Trulicity among 15 drugs for 2028 price negotiations. The stock has dropped three straight sessions and now trades about 8% below its Jan. 8 peak. Investors await Lilly’s Feb. 4 earnings for updates on diabetes and obesity drug trends.
28 January 2026
·······
Eli Lilly stock edges up as Roche obesity-drug data keeps weight-loss race in view

Eli Lilly stock edges up as Roche obesity-drug data keeps weight-loss race in view

Eli Lilly shares rose 0.4% to $1,067.38 Tuesday, outperforming a weaker health-care sector as investors awaited the company’s Feb. 4 results. Roche reported its experimental obesity drug CT-388 achieved up to 22.5% placebo-adjusted weight loss in a Phase II trial and plans two Phase III studies this quarter. Novo Nordisk shares slipped. Investors remain focused on demand and supply for Lilly’s weight-loss drugs.
27 January 2026
·
AbbVie stock price closes higher; what to watch next for ABBV ahead of Fed week and earnings

AbbVie stock price closes higher; what to watch next for ABBV ahead of Fed week and earnings

AbbVie shares closed up 0.7% at $220.77 on Monday, moving with broader Wall Street gains ahead of the Federal Reserve’s policy decision and major tech earnings. The company will report full-year and Q4 results before the market opens on Feb. 4. AbbVie recently signed a $650 million cancer drug licensing deal with RemeGen and faces investor scrutiny over its post-Humira growth strategy.
27 January 2026
···
Gilead stock ticks up after BMO lifts target to $150, flags Yeztugo coverage gains

Gilead stock ticks up after BMO lifts target to $150, flags Yeztugo coverage gains

Gilead Sciences shares rose 0.9% to $137.21 midday Monday after BMO Capital Markets raised its price target to $150, citing expanded insurance coverage for Yeztugo, Gilead’s new HIV prevention shot. CVS confirmed coverage starting Jan. 1, pushing overall insurer coverage above 80%. Gilead says it has already met its 2025 Yeztugo sales target of $150 million. Investors await Gilead’s earnings report, expected Feb. 10.
26 January 2026
·
Eli Lilly stock slips in late morning trade as investors size up earnings and the obesity-pill race

Eli Lilly stock slips in late morning trade as investors size up earnings and the obesity-pill race

Eli Lilly shares slipped 0.1% to $1,062.87 in late morning trading Monday, extending last week’s decline. Investors are focused on the Feb. 4 earnings release and updates on obesity drug launches amid rising competition from Novo Nordisk. Early U.S. sales of Novo’s oral Wegovy and anticipation for Lilly’s orforglipron pill are drawing analyst attention. Legal and pricing pressures add uncertainty as both firms battle for market share.
26 January 2026
···
Sarepta Therapeutics (SRPT) stock jumps premarket ahead of Elevidys EMBARK 3-year data

Sarepta Therapeutics (SRPT) stock jumps premarket ahead of Elevidys EMBARK 3-year data

Sarepta Therapeutics shares rose 6.5% to $22.51 in early premarket trading Monday, following a 9.65% after-hours surge Friday ahead of new Elevidys trial data. Investors await three-year results from the Phase 3 EMBARK study in Duchenne muscular dystrophy, with safety concerns heightened after FDA restrictions and patient deaths. About 17,600 shares changed hands premarket, according to Public.com.
26 January 2026
·
Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

Healthcare stocks brace for a key week: XLV slips as Wegovy pill data and UnitedHealth earnings loom

The Health Care Select Sector SPDR Fund (XLV) fell 0.5% to $157.48 Friday, with Eli Lilly down 2.1%. Johnson & Johnson and UnitedHealth posted small gains. Traders are watching obesity-drug demand and a crowded earnings calendar next week. The FDA linked ByHeart’s recalled infant formula to a multi-state botulism outbreak.
25 January 2026
·····
Roche stock hovers near a 52-week high as investors brace for Thursday’s results

Roche stock hovers near a 52-week high as investors brace for Thursday’s results

Roche participation shares closed Friday at 348.10 Swiss francs, up 0.06% and near a 52-week high. The company will report full-year 2025 results before the Swiss market opens on Jan. 29, followed by a management webcast. Investors are watching for 2026 guidance and updates on drug launches and diagnostics demand. The Swiss Market Index fell 0.61% Friday.
25 January 2026
···
AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

AbbVie stock price: India patent setback on Venclexta puts ABBV in focus before Feb. 4 earnings

AbbVie shares rose 0.5% to $219.26 Friday, shrugging off India’s rejection of its patent application for the cancer drug venetoclax. The Indian patent office cited lack of novelty and opposition from seven parties. AbbVie will report Q4 and full-year earnings on Feb. 4. Investors remain focused on patent risks and upcoming guidance as the company adjusts after Humira’s decline.
25 January 2026
···
1 … 7 8 9 10 11 … 38

Stock Market Today

  • U.S. Natural Gas Prices Drop on Warmer Weather, Supply Factors Sustain Pressure
    March 20, 2026, 5:19 PM EDT. Natural gas prices for April Nymex delivery fell 2.24% as US weather forecasts turned warmer, potentially lowering heating demand. The Commodity Weather Group predicts above-average temperatures in the western US through March 29, pressuring prices. However, a recent Iranian attack on Qatar's Ras Laffan LNG export facility, which supplies 20% of global liquefied natural gas, could limit further declines. US dry gas production rose 4.8% year-on-year, nearing record highs with rigs increasing to a 2.5-year peak. Inventories surged by 35 billion cubic feet last week, well above average, indicating ample supply. Despite these bearish signals, rising electricity output and export potential from Qatar's damaged plant could support prices amid global supply disruptions.
Go toTop